Epizyme, Inc.
METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES
Last updated:
Abstract:
The present disclosure relates to methods and compositions for treating immune-mediated diseases. In some aspects, the disclosure relates to methods for treating immune-mediated diseases by administering an EHMT2 inhibitor in combination with one or more treatment modalities (e.g. one or more therapeutic agents). In some aspects the immune-mediated disease is rheumatoid arthritis, multiple sclerosis, psoriasis, a psoriatic disorder, psoriatic arthritis, or an inflammatory bowel disease.
Status:
Application
Type:
Utility
Filling date:
18 Oct 2018
Issue date:
15 Jul 2021